Designed for the regulated market, not the recreational one.
GACP-aligned cultivation protocols, full traceability from seed to final product, and a strain catalogue built around clinically relevant cannabinoid and terpene profiles.
MedCana is a global holding company producing pharmaceutical-grade cannabis from the Antioquia highlands of Colombia. Seven licensed operations, a fully integrated supply chain, a first pharmaceutical-flower shipment to Australia in process, CBD delivered indirectly into Europe, and customers waiting across the EU.
Most cannabis companies do one thing — grow, distribute, or build technology. MedCana is built as an integrated operator: cultivation, in-house agrotech, and a supply chain that runs from genetics in the Antioquia highlands through to export.
GACP-aligned cultivation protocols, full traceability from seed to final product, and a strain catalogue built around clinically relevant cannabinoid and terpene profiles.
We acquired the licenses, the land, and the people. Our agrotech arm Eko2o builds the greenhouses and the irrigation systems — and our software arm, Tokan, is slated to develop the ERP that will tie the operation together as it scales.
MedCana is preparing its first shipment of pharmaceutical flower to Australia — in process as of June 4, 2026 — and has twice delivered CBD to Switzerland, indirectly through a Colombian partner. Pharmaceutical flower is legal in Colombia, with domestic sales pending clearance. The next CBD crop is being prepared for export to the Czech Republic. Brazil is a major future market.
A microclimate inside the equatorial band that produces, year-round, what most growers chase for six months a year.
Software Effective Solutions Corp. — traded as $SFWJ — is the public parent. Underneath sits a stack designed so that nothing critical to producing a pharmaceutical-grade flower or extract is outside our control.
Organic Leaves, Remedium, Vital Cannabis, Cannahealth Business, Cannabicolombian Group, Royal Cannabis de Colombia, and Elemental Genetics.
Designs and operates the greenhouses, irrigation, monitoring and climate-control systems across every farm.
A licensed entry point into one of the world's fastest-growing medical cannabis markets — 23.7% CAGR through 2030.
The traceability and operations platform planned to support the farms as MedCana scales — with SaaS licensing envisioned as a later phase.
A premium hybrid — 60% Indica, 40% Sativa — bred for a balanced cannabinoid expression and a dominant β-Caryophyllene / Limonene terpene profile. Total cannabinoids 17.85% on a dry-weight basis.
We supply pharmaceutical-grade flower, biomass, and extracts under our own licenses, with full lab documentation on every batch. Volume contracts welcome.
MedCana trades publicly as $SFWJ. The investor relations dossier covers the holding structure, the production ramp, and the global market thesis.